Sampsa Hautaniemi

Sampsa Hautaniemi is a Professor at the Department of Biochemistry and Developmental Biology within the Faculty of Medicine at the University of Helsinki. He serves as Principal Investigator of the Systems Biology of Drug Resistance in Cancer research group and holds docentship in the Faculty of Medicine. Professor Hautaniemi actively supervises doctoral students across multiple programs including the Doctoral Programme in Biomedicine, Doctoral Programme in Clinical Research, and Doctoral Programme in Integrative Life Science.

His research focuses on systems biology approaches to understand drug resistance mechanisms in cancer, particularly ovarian cancer. His work integrates computational biology, genomics, epigenetics, and bioinformatics to develop precision medicine approaches for cancer treatment. His laboratory develops innovative computational methods and experimental models including patient-derived organoids to study tumor evolution, identify therapeutic targets, and predict treatment responses.

Analysis of his recent publications reveals a strong emphasis on understanding tumor heterogeneity, clonal evolution during therapy, and the development of computational tools for cancer genomics. His work spans multiple disciplines including cancer biology, computational biology, immunology, and precision medicine, with a particular focus on high-grade serous ovarian cancer as a model system.

Scientific Awards:

• The Anders Jahre Medical Prize to young medical scientists (2014) for outstanding research on systems biology and cancer
• The Finnish Medical Foundation 50-years jubileum award (2010)

Professor Hautaniemi has supervised numerous doctoral students and early-career researchers, contributing significantly to cancer research education. His research is supported by multiple active projects including the DECIDER project (Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer) funded until 2026, as well as projects from the Academy of Finland, Cancer Foundation, and industry partners like Orion Corporation. His laboratory maintains a patient-derived organoid biobank for high-grade serous ovarian cancer and develops computational tools like Jellyfish for visualizing tumor evolution.